Ocular Therapeutix (NASDAQ:OCUL) Insider Sanjay Nayak Sells 10,348 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Sanjay Nayak sold 10,348 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total transaction of $93,545.92. Following the sale, the insider owned 332,412 shares in the company, valued at approximately $3,005,004.48. This trade represents a 3.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Ocular Therapeutix Stock Down 21.3%

Shares of NASDAQ:OCUL opened at $6.99 on Wednesday. The firm has a market capitalization of $1.52 billion, a PE ratio of -4.85 and a beta of 0.90. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.32 and a current ratio of 15.39. Ocular Therapeutix, Inc. has a 52-week low of $5.78 and a 52-week high of $16.44. The firm has a fifty day moving average of $11.22 and a 200 day moving average of $11.78.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.04. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The firm had revenue of $13.25 million during the quarter, compared to analyst estimates of $16.13 million. During the same quarter in the previous year, the company posted ($0.29) earnings per share. The company’s revenue was down 22.4% compared to the same quarter last year. As a group, research analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OCUL has been the topic of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $20.00 price target on shares of Ocular Therapeutix in a research report on Monday, December 8th. Wall Street Zen raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Thursday, January 22nd. Royal Bank Of Canada restated an “outperform” rating and set a $30.00 price target on shares of Ocular Therapeutix in a research report on Thursday, February 5th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, December 9th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Ocular Therapeutix News Summary

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: SOL‑1 demonstrated statistical superiority to Regeneron’s Eylea on the trial’s vision endpoint, supporting Ocular’s plan to pursue an FDA filing and a potential new treatment option in wet AMD. Ocular Therapeutix’s eye drug superior to Regeneron’s Eylea in late-stage trial
• Positive Sentiment: Company and coverage note a clear regulatory path — Ocular is talking about an FDA submission based on the Phase 3 win, which could materially change the company’s product mix if approved. Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
• Neutral Sentiment: Ocular released topline SOL‑1 results and corporate commentary; the data readout itself is positive but investors are parsing subgroup/endpoint details and next steps. Ocular Therapeutix releases positive topline results from SOL-1
• Negative Sentiment: Despite the win, shares fell sharply because the observed benefit was characterized as modest and, crucially, the comparator in some analyses was a lower‑dose/less‑favorable version of Eylea — raising questions about clinical meaningfulness and commercial differentiation. Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron’s Eylea
• Negative Sentiment: Market and analyst coverage flagged investor skepticism — headlines note a 25–35% intraday decline on heavy volume as traders focused on practical uptake, labeling the result “positive but underwhelming.” Ocular claims a win with eye drug data even as shares sink
• Negative Sentiment: Commentary points to potential regulatory and commercial hurdles (e.g., demonstrating meaningful advantage vs standard‑dose Eylea, pricing/reimbursement, and adoption), which could delay or limit upside even if FDA accepts a filing. Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Regeneron’s leading Eylea

Institutional Investors Weigh In On Ocular Therapeutix

Institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Ocular Therapeutix by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company’s stock worth $686,000 after acquiring an additional 5,156 shares during the last quarter. Caxton Associates LLP purchased a new stake in shares of Ocular Therapeutix during the first quarter worth about $248,000. KLP Kapitalforvaltning AS grew its stake in shares of Ocular Therapeutix by 36.2% in the second quarter. KLP Kapitalforvaltning AS now owns 23,700 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 6,300 shares during the last quarter. Allianz Asset Management GmbH grew its stake in shares of Ocular Therapeutix by 63.2% in the second quarter. Allianz Asset Management GmbH now owns 61,200 shares of the biopharmaceutical company’s stock worth $568,000 after purchasing an additional 23,700 shares during the last quarter. Finally, AlphaQuest LLC increased its holdings in Ocular Therapeutix by 200.8% during the 2nd quarter. AlphaQuest LLC now owns 20,196 shares of the biopharmaceutical company’s stock valued at $187,000 after purchasing an additional 13,483 shares during the period. Hedge funds and other institutional investors own 59.21% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.